CD8A and neoplasm: In our study, tumor-bearing mice treated therapeutically with MS-OVA generated OVA-specific CD8+ T cell responses in the blood that when compared to non-tumor bearing mice had a slightly lower number of IL-7Rα high cells and the same low number of CD62Lhigh cells at a time-point when the tumors were measured to be growing.